Assays for Fixed Dose Combinations of Anti-HER2 Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in analyzing the quality and quantity attributes of fixed dose combinations of anti-HER2 antibodies, particularly pertuzumab and trastuzumab, due to their structural and functional similarities, which complicates the application of usual analytical methods.
Innovation Solution
A binding assay is developed using a modified HER2 extracellular domain as a capture reagent, allowing for the specific quantification of antibody binding to HER2 subdomains II and IV, and ion exchange chromatography is employed to evaluate charge variants, enabling precise characterization of the antibodies in their native form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If usual analytical methods are applied to fixed dose combinations of anti-HER2 antibodies, then the analysis process is simplified, but the structural and functional similarities between the antibodies cause inaccurate differentiation and quantification
Solution Approach 1:
The patent segments the analysis by using two distinct capture reagents: one specific for pertuzumab and another specific for trastuzumab. Each capture reagent is designed to selectively bind its target antibody, allowing the two highly similar antibodies to be differentiated and quantified separately in the same sample without cross-interference
Solution Approach 2:
The patent introduces capture reagents as intermediary molecules that mediate the specific recognition and binding of each antibody. These capture reagents act as intermediaries between the sample containing both antibodies and the detection system, enabling selective capture and quantification of each antibody type through their unique binding specificities
2Stability of the object's composition
If ion exchange chromatography is used to characterize antibodies in native form, then the antibodies remain in their native conformation, but the method cannot resolve the two similar antibodies separately
Solution Approach 1:
The patent combines ion exchange chromatography with a segmented detection approach using two specific capture reagents. The chromatography separates antibodies by charge while the capture reagents provide specific recognition for each antibody type, allowing both native conformation preservation and individual quantification to be achieved simultaneously
Solution Approach 2:
The patent creates a multi-functional analytical system where ion exchange chromatography provides separation based on charge properties while capture reagents provide specific antibody recognition. This universal approach handles both the structural characterization requirement and the specific quantification requirement in a single integrated workflow
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables effective control of product quality and potency of the fixed dose combination by accurately measuring antibody binding and charge variants, ensuring the synergistic effect and safety efficacy of pertuzumab and trastuzumab.
Implementation Method 1
contacting the FDC with a capture reagent comprising a modified HER2 ECD subdomain
Implementation Method 2
Ion-exchange chromatography (IEX) is widely used for the detailed characterization of therapeutic proteins and can be considered as a reference and powerful technique for the qualitative and quantitative evaluation of charge heterogeneity
Implementation Method 3
For most biopharmaceutical agents, the protein content is measured by UV absorption
Data Source
AI summary
Assays to analyze quality and quantity attributes of fixed dose combinations are provided. In particular, assays for fixed dose combinations of two anti-HER2 antibodies, and for subcutaneous formulations comprising pertuzumab and trastuzumab are described herein.